CLINICAL TRIALS PROFILE FOR TETANUS AND DIPHTHERIA TOXOIDS ADSORBED
✉ Email this page to a colleague
All Clinical Trials for tetanus and diphtheria toxoids adsorbed
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00707148 ↗ | Pertussis Vaccine in Healthy Pregnant Women | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | 2009-01-01 | The purpose of this study is to look at the safety and immunogenicity of a combination vaccine that includes tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap). The study will be conducted in 48 pregnant women and 32 non-pregnant women. Safety of the newborn infant and the effect of the mother's vaccination on the infants' immune responses prior to vaccinating infants with another combination vaccine to protect against diphtheria, tetanus, and pertussis will be evaluated. Participants will be 18-45 years old. Pregnant volunteers will be 30-32 weeks pregnant and at a low risk for pregnancy complications. Pregnant volunteers will receive 2 injections (1 vaccine and 1 placebo, inactive substance); non-pregnant volunteers will receive 1 injection of vaccine. Blood samples will be collected from the mother and infant, along with the baby's growth measurements. Participation for mother infant pairs is about 15 months and about 7 months for non-pregnant women. |
| NCT02193347 ↗ | IDH1 Peptide Vaccine for Recurrent Grade II Glioma | Active, not recruiting | Gary Archer Ph.D. | Phase 1 | 2016-01-28 | Potential subjects with progressive Grade II primary brain tumor that have IDH1 positive testing from the primary tumor (initial diagnosis) will be offered this treatment study in order to test the safety of the PEPIDH1M vaccine in combination with standard chemotherapy (temozolomide). |
| NCT02529072 ↗ | Nivolumab With DC Vaccines for Recurrent Brain Tumors | Completed | Bristol-Myers Squibb | Phase 1 | 2016-01-01 | Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab alone and with DC vaccine therapy until surgical resection. During surgical resection blood and tumor samples will be assessed and compared. Following surgery, both groups will continue to receive DC vaccines (total of 8) and nivolumab therapy until confirmed progression. |
| NCT02529072 ↗ | Nivolumab With DC Vaccines for Recurrent Brain Tumors | Completed | Duke Cancer Institute | Phase 1 | 2016-01-01 | Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab alone and with DC vaccine therapy until surgical resection. During surgical resection blood and tumor samples will be assessed and compared. Following surgery, both groups will continue to receive DC vaccines (total of 8) and nivolumab therapy until confirmed progression. |
| NCT02529072 ↗ | Nivolumab With DC Vaccines for Recurrent Brain Tumors | Completed | Gary Archer Ph.D. | Phase 1 | 2016-01-01 | Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab alone and with DC vaccine therapy until surgical resection. During surgical resection blood and tumor samples will be assessed and compared. Following surgery, both groups will continue to receive DC vaccines (total of 8) and nivolumab therapy until confirmed progression. |
| NCT03927222 ↗ | Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma | Suspended | Gary Archer Ph.D. | Phase 2 | 2019-09-30 | This single-arm phase II study will assess the impact of tetanus pre-conditioning and adjuvant Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) on overall survival of patients newly diagnosed with World Health Organization (WHO) Grade IV glioblastoma who have undergone definitive tumor resection, are cytomegalvirus (CMV) positive and unmethylated, and completed standard temozolomide (TMZ) and radiation treatment. After completion of the standard of care radiotherapy with concurrent TMZ, patients will receive 1 cycle of dose-intensified TMZ followed by pp65-loaded dendritic cell (DC) vaccination beginning on day 23. |
| NCT05609994 ↗ | ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas | Not yet recruiting | Servier | Phase 1 | 2023-01-01 | The purpose of this study is to determine the safety and efficacy of a PEPIDH1M vaccine in combination with vorasidenib, a dual inhibitor of mutant IDH1 and IDH2 enzymes, in adult patients diagnosed with recurrent IDH1 mutant lower grade gliomas. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for tetanus and diphtheria toxoids adsorbed
Condition Name
Clinical Trial Locations for tetanus and diphtheria toxoids adsorbed
Trials by Country
Clinical Trial Progress for tetanus and diphtheria toxoids adsorbed
Clinical Trial Phase
Clinical Trial Sponsors for tetanus and diphtheria toxoids adsorbed
Sponsor Name
